-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Needham & Company LLC Initiates Coverage on Cogent Biosciences (NASDAQ:COGT)
Needham & Company LLC Initiates Coverage on Cogent Biosciences (NASDAQ:COGT)
Needham & Company LLC assumed coverage on shares of Cogent Biosciences (NASDAQ:COGT – Get Rating) in a research note issued on Wednesday, The Fly reports. The brokerage set a "buy" rating and a $24.00 price target on the technology company's stock. Needham & Company LLC's price objective would indicate a potential upside of 98.35% from the company's previous close.
A number of other brokerages also recently commented on COGT. Wedbush lowered their target price on Cogent Biosciences to $19.00 in a research note on Wednesday, November 16th. SVB Leerink lowered their target price on Cogent Biosciences from $20.00 to $18.00 and set an "outperform" rating on the stock in a research note on Thursday, November 17th. Finally, Guggenheim boosted their target price on Cogent Biosciences from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday.
Get Cogent Biosciences alerts:Cogent Biosciences Trading Up 1.3 %
Shares of COGT stock opened at $12.10 on Wednesday. Cogent Biosciences has a 1-year low of $3.79 and a 1-year high of $18.07. The company has a market capitalization of $554.41 million, a price-to-earnings ratio of -4.84 and a beta of 1.67. The stock's fifty day simple moving average is $12.49 and its 200-day simple moving average is $12.21.
Hedge Funds Weigh In On Cogent Biosciences
Several large investors have recently added to or reduced their stakes in COGT. Veritable L.P. raised its holdings in Cogent Biosciences by 14.4% in the 1st quarter. Veritable L.P. now owns 57,020 shares of the technology company's stock valued at $427,000 after acquiring an additional 7,180 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of Cogent Biosciences by 285.8% in the 1st quarter. MetLife Investment Management LLC now owns 16,460 shares of the technology company's stock valued at $123,000 after purchasing an additional 12,193 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Cogent Biosciences by 66.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 71,423 shares of the technology company's stock valued at $535,000 after purchasing an additional 28,422 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Cogent Biosciences in the 1st quarter valued at approximately $86,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in shares of Cogent Biosciences in the 1st quarter valued at approximately $19,862,000.Cogent Biosciences Company Profile
(Get Rating)
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Featured Stories
- Get a free copy of the StockNews.com research report on Cogent Biosciences (COGT)
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Needham & Company LLC assumed coverage on shares of Cogent Biosciences (NASDAQ:COGT – Get Rating) in a research note issued on Wednesday, The Fly reports. The brokerage set a "buy" rating and a $24.00 price target on the technology company's stock. Needham & Company LLC's price objective would indicate a potential upside of 98.35% from the company's previous close.
據The Fly報道，Needham&Company LLC在週三發佈的一份研究報告中假設了科興生物科學公司(Cogt-Get Rating)的股票。該經紀公司為這家科技公司的股票設定了“買入”評級和24美元的目標價。Needham&Company LLC的目標價顯示，該公司較前一交易日收盤價可能上漲98.35%。
A number of other brokerages also recently commented on COGT. Wedbush lowered their target price on Cogent Biosciences to $19.00 in a research note on Wednesday, November 16th. SVB Leerink lowered their target price on Cogent Biosciences from $20.00 to $18.00 and set an "outperform" rating on the stock in a research note on Thursday, November 17th. Finally, Guggenheim boosted their target price on Cogent Biosciences from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday.
其他一些券商最近也對COGT發表了評論。韋德布什在11月16日星期三的一份研究報告中將他們對Cogent Biosciences的目標價下調至19.00美元。SVB Leerink在11月17日週四的一份研究報告中將Cogent Biosciences的目標價從20.00美元下調至18.00美元，並對該股設定了“跑贏大盤”的評級。最後，古根海姆週二在一份研究報告中將Cogent Biosciences的目標價從22.00美元上調至24.00美元，並給予該公司“買入”評級。
Cogent Biosciences Trading Up 1.3 %
令人信服的生物科學公司股價上漲1.3%
Shares of COGT stock opened at $12.10 on Wednesday. Cogent Biosciences has a 1-year low of $3.79 and a 1-year high of $18.07. The company has a market capitalization of $554.41 million, a price-to-earnings ratio of -4.84 and a beta of 1.67. The stock's fifty day simple moving average is $12.49 and its 200-day simple moving average is $12.21.
週三，COGT的股票開盤報12.10美元。Coent Biosciences的一年低點為3.79美元，一年高位為18.07美元。該公司市值為5.541億美元，本益比為-4.84倍，貝塔係數為1.67。該股的50日簡單移動均線為12.49美元，200日簡單移動均線為12.21美元。
Hedge Funds Weigh In On Cogent Biosciences
對沖基金對Cogent Bioscions的看法
Cogent Biosciences Company Profile
令人信服的生物科學公司簡介
(Get Rating)
(獲取評級)
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Cogent Biosciences，Inc.是一家生物技術公司，專注於為基因定義的疾病開發精確療法。它的主要候選產品包括CGT9486，一種選擇性酪氨酸激酵素抑制劑，旨在抑制導致系統性肥大細胞增多的KIT D816V突變，以及KIT外顯子17的其他突變，這些突變在晚期胃腸道間質瘤患者中發現。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Cogent Biosciences (COGT)
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
- 免費獲取StockNews.com關於Cogent Biosciences(COGT)的研究報告
- 企業產品合作夥伴是否得到公平評價？
- WhatsApp合作夥伴關係是否會提振MercadoLibre的收益？
- 2023年中型股可能翻一番
- 馬倫汽車簽署新合作夥伴後股價上漲
- REV集團引領專用車製造商走高
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Cogent Bioscions Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cogent Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧